Jacobio Pharmaceuticals (HKG:1167) plans to repurchase shares worth up to HK$100 million under a mandate approved by shareholders at its annual general meeting on June 5, according to a Monday Hong Kong bourse filing.
The company is authorized to repurchase up to 78.4 million shares, representing 10% of its issued share capital, excluding treasury shares.
Jacobio said the buybacks will be funded from internal resources and may continue until the mandate expires, subject to market conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.